| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.04 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.05 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.076 | 0.05 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.05 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.05 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.06 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.069 | 0.06 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.071 | 0.06 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.06 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.072 | 0.06 |